Examples of using Study entry in English and their translations into Italian
{-}
-
Medicine
-
Colloquial
-
Official
-
Financial
-
Ecclesiastic
-
Ecclesiastic
-
Computer
-
Programming
-
Official/political
The age range at study entry was 1-6 months.
count of 19 x 109/ l at study entry.
Baseline ICS use at study entry was recorded, but not required in the study. .
The majority(75%) of patients had M1c stage disease at study entry.
Detailed clinical status information will be collected at study entry and on an annual basis for at least 15 years.
People also translate
A KRAS mutation was reported in 57% of patients at study entry.
had measurable soft tissue disease at study entry, and 12% of patients had visceral(lung and/or liver) metastases.
ITP for approximately 2 years at the time of study entry.
190 mg/dl at study entry, and 24% of patients with LDL-cholesterol>
and≥1 gadolinium-enhancing lesion at study entry.
The most commonly taken AEDs at the time of study entry were carbamazepine(40.6%),
The median cumulative RAI activity administered prior to study entry was 350 mCi 12.95 GBq.
not considered amenable to further resective surgery at the time of study entry.
standardised dose of prednisone 60 mg/day at study entry followed by a mandatory taper schedule, with
subjects were HPV DNA positive at study entry.
heart failure had confounding factors at study entry, and the causality assessment of investigators for all deaths ascribed
37% of patients had a baseline LDH level greater than ULN at study entry.
At the time of study entry, patients had been clinically stable
were failing a PI-based regimen at the time of study entry.
patients receiving lamivudine at study entry either switched to entecavir 1 mg once daily,
baseline LDH level greater than ULN at study entry.
Candida species from a normally sterile site before study entry were included in the modified intent- to-treat(MITT) population.
were not in major cytogenetic response at time of study entry.
task after treatment versus task-induced values observed at study entry and greater than pre-/posttreatment changes seen in patients randomized to the WLC.
5.1“Efficacy in women with evidence of HPV-16 or HPV-18 infection at study entry.”.
12 mg/day for 5 consecutive days at study entry and for 3 consecutive days at Study Month 12.
54% had dyslipidaemia at study entry, and 11% had type 2 diabetes.
age-specific normal reference range at the time of study entry) confirmed by radiographic evidence.
age-specific normal reference range at the time of study entry) confirmed by radiographic evidence.